CliffBio
small molecule

SAPHRIS

ASENAPINE MALEATE

Loss of exclusivityOctober 2026latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameSAPHRIS
Active ingredientASENAPINE MALEATE
StrengthEQ 5MG BASE
Dosage formTABLET
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalAugust 2009
Marketing statusRX

Listed patents

PatentExpiresType
7741358*PEDOctober 2026—
8022228*PEDOctober 2026—
7741358April 2026substance, product
8022228April 2026substance, product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.